Adoptive T-cell therapies are promising, but fall short in longer-term tumour clearance, with poor efficacy against #SolidTumours 📉
This new article explores how #optogenetics are being applied to improve #ATC therapies 👉 bit.ly/3Poqw5o
This new article explores how #optogenetics are being applied to improve #ATC therapies 👉 bit.ly/3Poqw5o
January 9, 2025 at 4:19 PM
Adoptive T-cell therapies are promising, but fall short in longer-term tumour clearance, with poor efficacy against #SolidTumours 📉
This new article explores how #optogenetics are being applied to improve #ATC therapies 👉 bit.ly/3Poqw5o
This new article explores how #optogenetics are being applied to improve #ATC therapies 👉 bit.ly/3Poqw5o
📈 #RWE publications evaluating #targetedtherapies in pts w/ #solidtumours
#RWD quality standards & ⬆️ collaboration will be 🔑 to increase the relevance of #RWE for informing clinical practice and decision making 🌍
#RWD quality standards & ⬆️ collaboration will be 🔑 to increase the relevance of #RWE for informing clinical practice and decision making 🌍
RWE is becoming increasingly vital in cancer research
To improve quality, we need to understand where we stand
Happy to share this major effort analyzing 1251 studies mapping RWE
Standardization & ⬆️ collaboration will be 🔑 to increase the relevance of RWD
@oncoalert.bsky.social
To improve quality, we need to understand where we stand
Happy to share this major effort analyzing 1251 studies mapping RWE
Standardization & ⬆️ collaboration will be 🔑 to increase the relevance of RWD
@oncoalert.bsky.social
December 5, 2024 at 7:24 AM
📈 #RWE publications evaluating #targetedtherapies in pts w/ #solidtumours
#RWD quality standards & ⬆️ collaboration will be 🔑 to increase the relevance of #RWE for informing clinical practice and decision making 🌍
#RWD quality standards & ⬆️ collaboration will be 🔑 to increase the relevance of #RWE for informing clinical practice and decision making 🌍
Jiangsu #Hengrui Pharma's oral thrombopoietin (#TPO) receptor agonist #hetrombopag has been approved in #China to treat low platelet counts (thrombocytopenia) caused by #chemotherapy for #solidtumours.
buff.ly/acx4yvZ
buff.ly/acx4yvZ
September 11, 2026 at 3:00 PM
Jiangsu #Hengrui Pharma's oral thrombopoietin (#TPO) receptor agonist #hetrombopag has been approved in #China to treat low platelet counts (thrombocytopenia) caused by #chemotherapy for #solidtumours.
buff.ly/acx4yvZ
buff.ly/acx4yvZ
#HongKong biopharma company #Akeso has secured clinical trial clearance in #China for a next-generation antibody-drug conjugate (#ADC) targeting B7-H3, paving the way for a Phase I study in patients with advanced #solidtumours.
pharmaphorum.com/news/akeso-a...
pharmaphorum.com/news/akeso-a...
Akeso and CStone secure China clearances for next-generation ADCs
Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
pharmaphorum.com
August 21, 2026 at 10:13 AM
#HongKong biopharma company #Akeso has secured clinical trial clearance in #China for a next-generation antibody-drug conjugate (#ADC) targeting B7-H3, paving the way for a Phase I study in patients with advanced #solidtumours.
pharmaphorum.com/news/akeso-a...
pharmaphorum.com/news/akeso-a...
#Moderna #skincancervaccine #MSD #mRNAbasedvaccine #melanoma #intismeranautogene #mRNA4157 #KEYNOTE942study #cancervaccine #highriskmelanoma #personalisedvaccine #cancerneoantigens #lungcancer #kidneycancer #bladdercancer #INTerpath001trial #solidtumours #oncology #clinicaldevelopment
zurl.co/fwe5k
zurl.co/fwe5k
Data builds behind Moderna's skin cancer vaccine
Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
pharmaphorum.com
January 26, 2026 at 10:22 AM
#Iktos #PierreFabre #oncology #PierreFabreLaboratories #AIdrugdiscovery #roboticsdrugdiscovery #smallmoleculedrugcandidates #generativeAI #EICAccelerator #PierreFabreMedicalCare #generativeAI #precisiononcology #NSCLC #nonsmallcelllungcancer #solidtumours #rarediseases
zurl.co/Gx2yL
zurl.co/Gx2yL
Now Iktos teams up with Pierre Fabre in oncology
As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
pharmaphorum.com
January 14, 2026 at 12:12 PM
#oncology #AbbVie #solidtumourtherapies #ADCs #antibodydrugconjugate #ADCplatform #solidtumours #ESMO2025 #pancreaticcancer #colorectalcancer #solidtumourtypes #ADCcandidates #clinicaldevelopment #innovativetherapies #patientoutcomes #clinicalstrategies #regulatory
zurl.co/AmIT3
zurl.co/AmIT3
AbbVie unveils new data on solid tumour therapies - PharmaTimes
Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers
pharmatimes.com
October 20, 2025 at 1:43 PM
#Celltherapy #eXmoorpharma #SignadoriBio #solidtumours #Signadori #solidcancers #genemodifiedmonocytederivedmacrophagecelltherapyprogramme #cellandgenetherapy #genemodifiedmonocytes #translationalscience #nextgenerationmonocytebasedtherapies
pharmatimes.com/news/exmoor-...
pharmatimes.com/news/exmoor-...
eXmoor and Signadori Bio enter cell therapy partnership - PharmaTimes
Signadori is advancing a platform designed to overcome the challenges of treating solid cancers
pharmatimes.com
June 25, 2025 at 8:37 AM
#Bayer #precisiononcology #oncology #SOS1inhibitorstudy #BAY3498264 #KRASmutatedcancers #nonsmallcelllungcancer #lungcancer #NSCLC #pancreaticcancer #colorectalcancer #MAPKsignallingpathway #KRAStargetingagent #KRASmutatedcancers #solidtumours
pharmatimes.com/news/bayer-b...
pharmatimes.com/news/bayer-b...
Bayer begins inhibitor study treating advanced KRAS-mutated tumours - PharmaTimes
Trial explores potential of therapy in treating multiple cancer types
pharmatimes.com
December 12, 2024 at 1:58 PM
#AstraZeneca's push into #CART therapies for #cancer has continued with an agreement to take full control of C-CAR031, an #antiGPC3 therapy for #solidtumours, from #AbelZeta.
pharmaphorum.com/news/astraze...
pharmaphorum.com/news/astraze...
AstraZeneca pays $630m to get full control of AbelZeta CAR-T
AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.
pharmaphorum.com
January 20, 2026 at 11:57 AM
#AstraZeneca's push into #CART therapies for #cancer has continued with an agreement to take full control of C-CAR031, an #antiGPC3 therapy for #solidtumours, from #AbelZeta.
pharmaphorum.com/news/astraze...
pharmaphorum.com/news/astraze...
📄 [Press Release] - MaaT Pharma Presents Peclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
👉 Read the press release: www.maatpharma.com/april-28-202...
#Oncology #Microbiome #AACR #Preclinical #InVivo #InVitro #SolidTumours #Immunotherapies
👉 Read the press release: www.maatpharma.com/april-28-202...
#Oncology #Microbiome #AACR #Preclinical #InVivo #InVitro #SolidTumours #Immunotherapies
April 28, 2025 at 4:37 PM
📄 [Press Release] - MaaT Pharma Presents Peclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
👉 Read the press release: www.maatpharma.com/april-28-202...
#Oncology #Microbiome #AACR #Preclinical #InVivo #InVitro #SolidTumours #Immunotherapies
👉 Read the press release: www.maatpharma.com/april-28-202...
#Oncology #Microbiome #AACR #Preclinical #InVivo #InVitro #SolidTumours #Immunotherapies
#ESMOTATAsia26: Two novel CD47-SIRPα axis #FusionProteins with reduced haematological toxicity show promise in early-phase #ClinicalTrials in patients with heavily pre-treated #SolidTumours. More details in the #ESMODailyReporter: https://ow.ly/1MqO50ZbpBh
June 13, 2026 at 7:10 AM
#ESMOTATAsia26: Two novel CD47-SIRPα axis #FusionProteins with reduced haematological toxicity show promise in early-phase #ClinicalTrials in patients with heavily pre-treated #SolidTumours. More details in the #ESMODailyReporter: https://ow.ly/1MqO50ZbpBh
Agregar la terapia dirigida a metástasis a la terapia sistémica estándar para la enfermedad oligometastásica mejora la supervivencia libre de progresión, dependiendo del DNA tumoral circulante #MDT #oligometastasic #SolidTumours ascopubs.org/doi/abs/10.1...
ASCO Publications
ascopubs.org
May 25, 2026 at 8:13 AM
Agregar la terapia dirigida a metástasis a la terapia sistémica estándar para la enfermedad oligometastásica mejora la supervivencia libre de progresión, dependiendo del DNA tumoral circulante #MDT #oligometastasic #SolidTumours ascopubs.org/doi/abs/10.1...